ArticleJournal of gastroenterology2025
Comparison of outcomes between surgery and chemoradiotherapy after endoscopic resection for pT1a-MM with lymphovascular invasion or pT1b esophageal squamous cell carcinoma: Japanese multicenter propensity score-matched study.
Article in Journal of gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Long-term outcomes of additional surgical versus nonsurgical treatment after non-curative endoscopic resection for T1 superficial esophageal cancer.International journal of surgery (London, England) · 2026Pooled it
- Comparative efficacy and outcomes of different treatments for pathologically high-risk superficial esophageal cancer: a systematic review and network meta-analysis.Frontiers in oncology · 2026Pooled it
- Comparison of the efficacy of different treatments after non-curative endoscopic resection of superficial esophageal carcinoma: a meta-analysis.Frontiers in oncology · 2025Pooled it
- [Endoscopic diagnostics and treatment of early neoplasia of the esophagus].Chirurgie (Heidelberg, Germany) · 2026Review
- Efficacy and safety of endoscopic resection followed by chemoradiotherapy with S-1 plus cisplatin for esophageal cancer.International journal of clinical oncology · 2026Article
- Community standard practices in the endoscopic treatment of esophageal squamous cell carcinoma: a nationwide survey in Japan.Esophagus : official journal of the Japan Esophageal Society · 2026Article
- A novel esophagus-preserving strategy for T1b esophageal cancer combining endoscopic submucosal dissection and thoracoscopic lymph nodes sampling: the first case series.Journal of thoracic disease · 2026Article
- Next step after endoscopic resection for superficial esophageal squamous cell carcinoma: metastatic risk assessment and management of non-curative resection cases.Clinical endoscopy · 2026Review
- Endoscopic Submucosal Dissection and Chemoradiotherapy versus Esophagectomy for T1a-m3 or T1b Esophageal Squamous Cell Carcinoma: A Meta-analysis.Endoscopy international open · 2026Review
- Organ preservation in esophageal cancer treatment, is it time now?World journal of gastroenterology · 2025Review
- Treatment choices after endoscopic resection for pMM/SM1 esophageal squamous cell cancer: a retrospective study in China.Surgical endoscopy · 2025Article
- Additional esophagectomy after non-curative endoscopic treatment of superficial esophageal cancer can achieve better local control than additional chemoradiation therapy: a propensity score-matched analysis in a single center.Esophagus : official journal of the Japan Esophageal Society · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLymphovascular invasion (LVI) or pT1b is noncurative after endoscopic resection (ER) for esophageal squamous cell carcinoma (ESCC), and therefore surgery or chemoradiotherapy (CRT) is recommended. However, there has been debate regarding which treatment has better outcomes and whether individual risks should be considered.
methodsThis was a multicenter, retrospective study conducted at 65 hospitals in Japan. The inclusion criteria were patients with ESCC who underwent ER between January 2006 and December 2015, with pT1a-muscularis mucosa (MM) with LVI or pT1b, with negative vertical margins, cN0M0, and who underwent surgery or CRT. A 1:1 propensity score-matched analysis was performed between two groups. The primary and secondary end points were overall survival (OS) and relapse-free survival (RFS). OS and RFS were also compared between two subgroups: low risk (pT1a-MM with LVI and pT1b without LVI) and high risk (pT1b with LVI) for metastatic recurrence.
resultsAmong 472 patients, 160 patients were selected from each group. The OS and RFS did not differ between surgery and CRT groups (hazard ratio, 0.887; P = .635 and hazard ratio, 1.036; P = .876, respectively). Subgroup analysis showed that CRT had a better prognosis in the low-risk group, and conversely, surgery had a better prognosis in the high-risk group. But these were not significant. The high-risk CRT group had a significant worse prognosis than the low-risk CRT group.
conclusionsIn patients with noncurative ER for ESCC, surgery and CRT showed no difference in long-term outcomes. Indications for CRT in the high-risk group need further investigation because of poor prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.